Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AbbVie Inc.    0QCV

ABBVIE INC.

(0QCV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

AbbVie : Under Rule 8.1

share with twitter share with LinkedIn share with facebook
share via e-mail
03/30/2020 | 06:01am EDT

AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director

NORTH CHICAGO, Ill., March 30, 2020 /PRNewswire/ -- AbbVie issued the following form today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION
Name of person dealing  (Note 1) Richard Gonzalez
Company dealt in AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2) Common shares, par value $0.01 per share
Date of dealing 25 March 2020

   

2. INTERESTS AND SHORT POSITIONS
(a)Interests and short positions (following dealing) in the class of relevant security dealt in
(Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 377,893 Common Shares (0.00025%)
(2) Derivatives (other than options) N/A
(3) Options and agreements to purchase/sell 1,161,286 options (0.0008%)
Total 1,539,178 (0.00104%)
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
  (2) Derivatives (other than options)
  (3) Options and agreements to purchase/sell
Total

   

3. DEALINGS  (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit  (Note 5)
Withholding of common shares to satisfy tax obligations 56,950 common shares $0

   

(b) Derivatives transactions (other than options transactions)
Product name,
e.g. CFD
Nature of transaction
(Note 6)
Number of relevant securities
(Note 7)
Price per unit
(Note 5)

   

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,
e.g. call option
Writing, selling, 
purchasing, 
varying etc.
Number of securities 
to which the option 
relates 
(Note 7)
Exercise 
price
Type, e.g. 
American, 
European etc.
Expiry 
date
Option money 
paid/received 
per unit 
(Note 5)

   

(ii) Exercising
Product name,
e.g. call option
Number of securities Exercise price per unit  (Note 5)

   

(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction
(Note 8)
Details Price per unit
(if applicable)
(Note 5)

   

4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached?  (Note 9)  YES/NO?
Date of disclosure 27 March 2020
Contact name Steven L. Scrogham
Telephone number 847-938-6166
Name of offeree/offeror with which acting in concert AbbVie Inc.
Specify category and nature of acting in concert status Director of AbbVie Inc.

CONTACT: Adelle Infante, 1-847-938-8745


© PRNewswire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBVIE INC.
12:59pABBVIE : Gets FDA OK of Oriahnn for Fibroid-Related Heavy Menstrual Bleeding
DJ
05/28ABBVIE : Presents New Data at the European E-Congress of Rheumatology 2020 Showc..
AQ
05/27IRONWOOD PHARMACEUTICALS : Shares of Ironwood Move Lower Premarket After Study F..
DJ
05/27ABBVIE : Presents New Data at the European E-Congress of Rheumatology (EULAR) 20..
PR
05/21ABBVIE : Synlogic Shares Fall as AbbVie Collaboration Ends
DJ
05/18ABBVIE : Data at EHA Annual Congress Highlight Depth and Breadth of Transformati..
AQ
05/16Wall Street Week Ahead: Investors prepare for more U.S. stock swings as state..
RE
05/14ABBVIE : Completion of Acquisition or Disposition of Assets, Financial Statement..
AQ
05/14ABBVIE INC. : Entry into a Material Definitive Agreement, Creation of a Direct F..
AQ
05/14Allergan, Ideal Implant Issued Warning Letters From FDA Related to Breast Imp..
DJ
More news